The Serono Maia Clone prostatic-specific antigen (PSA) kit incorporates an immunoradiometric assay for the measurement of PSA in the serum. The method can be used over a range of 0-100 ng/ml without dilution. Standard concentrations are 0. 0.4, 1. 5, 20, and 100 ng/ml. Up to date, 373 normal men, 89 normal women, 117 prostatic carcinoma, 98 other carcinoma, and 85 benign prostatic hypertrophy have been tested. The aim of this study is to evaluate the sensitivity and specificity of a new immunoassay method for the determination of PSA, that could be able to evaluate low levels of PSA, resulted undetectable with other methods. This ability could be useful in patients treated with hormone-suppressive therapy or after radical prostatectomy. We have collected all low values present in samples examined. With the Serono Maia Clone PSA kit only 26.7% of these have been evaluated as 'out' values as opposed to 46.5% with the Hybritech kit.

NEW ULTRASENSITIVE ASSAY DEVELOPMENT BY USING MONOCLONAL-ANTIBODIES FOR DETECTING PROSTATE-SPECIFIC ANTIGEN / DI SILVERIO, Franco; D'Eramo, Giuseppe; G. P., Flammia; M., Caponera; D., Macri; A., Loreto; Sciarra, Alessandro. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - STAMPA. - 21:1(1992), pp. 79-82. (Intervento presentato al convegno 2ND MEDITERRANEAN CONGRESS OF UROLOGY : MARKERS IN UROLOGY tenutosi a ROME, ITALY nel JUL 03-06, 1991).

NEW ULTRASENSITIVE ASSAY DEVELOPMENT BY USING MONOCLONAL-ANTIBODIES FOR DETECTING PROSTATE-SPECIFIC ANTIGEN

DI SILVERIO, Franco;D'ERAMO, Giuseppe;SCIARRA, Alessandro
1992

Abstract

The Serono Maia Clone prostatic-specific antigen (PSA) kit incorporates an immunoradiometric assay for the measurement of PSA in the serum. The method can be used over a range of 0-100 ng/ml without dilution. Standard concentrations are 0. 0.4, 1. 5, 20, and 100 ng/ml. Up to date, 373 normal men, 89 normal women, 117 prostatic carcinoma, 98 other carcinoma, and 85 benign prostatic hypertrophy have been tested. The aim of this study is to evaluate the sensitivity and specificity of a new immunoassay method for the determination of PSA, that could be able to evaluate low levels of PSA, resulted undetectable with other methods. This ability could be useful in patients treated with hormone-suppressive therapy or after radical prostatectomy. We have collected all low values present in samples examined. With the Serono Maia Clone PSA kit only 26.7% of these have been evaluated as 'out' values as opposed to 46.5% with the Hybritech kit.
1992
prostate cancer; prostate cancer follow-up; prostate cancer screening; prostate-specific antigen; tumor marker
01 Pubblicazione su rivista::01a Articolo in rivista
NEW ULTRASENSITIVE ASSAY DEVELOPMENT BY USING MONOCLONAL-ANTIBODIES FOR DETECTING PROSTATE-SPECIFIC ANTIGEN / DI SILVERIO, Franco; D'Eramo, Giuseppe; G. P., Flammia; M., Caponera; D., Macri; A., Loreto; Sciarra, Alessandro. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - STAMPA. - 21:1(1992), pp. 79-82. (Intervento presentato al convegno 2ND MEDITERRANEAN CONGRESS OF UROLOGY : MARKERS IN UROLOGY tenutosi a ROME, ITALY nel JUL 03-06, 1991).
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/480339
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact